BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, Nguyen L, Thomas S, Cainzos-Achirica M, Rothman KJ, Andrews EB, Anthony MS. Cardiovascular Safety During and After Use of Phentermine and Topiramate. J Clin Endocrinol Metab 2019;104:513-22. [PMID: 30247575 DOI: 10.1210/jc.2018-01010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Bays HE, Lazarus E, Primack C, Fitch A. Obesity pillars roundtable: Phentermine – Past, present, and future. Obesity Pillars 2022;3:100024. [DOI: 10.1016/j.obpill.2022.100024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Raman V, Gupta A, Ashraf AP, Breidbart E, Gourgari E, Kamboj M, Kohn B, Krishnan S, Lahoti A, Matlock K, Mehta S, Mistry S, Miller R, Page L, Reynolds D, Han JC. Pharmacologic Weight Management in the Era of Adolescent Obesity. J Clin Endocrinol Metab 2022:dgac418. [PMID: 35932277 DOI: 10.1210/clinem/dgac418] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Jeong D, Priefer R. Anti-obesity weight loss medications: Short-term and long-term use. Life Sci 2022;306:120825. [PMID: 35870619 DOI: 10.1016/j.lfs.2022.120825] [Reference Citation Analysis]
4 Oroko, M, Llano, and A, Fisher M. Other Antidiabetic Drugs. Diabetes Drug Notes 2022. [DOI: 10.1002/9781119785033.ch13] [Reference Citation Analysis]
5 Bays HE, Kulkarni A, German C, Satish P, Iluyomade A, Dudum R, Thakkar A, Rifai MA, Mehta A, Thobani A, Al-saiegh Y, Nelson AJ, Sheth S, Toth PP. Ten Things to Know About Ten Cardiovascular Disease Risk Factors – 2022. American Journal of Preventive Cardiology 2022. [DOI: 10.1016/j.ajpc.2022.100342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Tahrani AA, Morton J. Benefits of weight loss of 10% or more in patients with overweight or obesity: A review. Obesity (Silver Spring) 2022;30:802-40. [PMID: 35333446 DOI: 10.1002/oby.23371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Pulipati VP, Pannain S. Pharmacotherapy of obesity in complex diseases. Clin Obes 2021;:e12497. [PMID: 34889046 DOI: 10.1111/cob.12497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ahmad NN, Robinson S, Kennedy-Martin T, Poon JL, Kan H. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review. Obes Rev 2021;22:e13326. [PMID: 34423889 DOI: 10.1111/obr.13326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Iwamoto SJ, Abushamat LA, Zaman A, Millard AJ, Cornier MA. Obesity Management in Cardiometabolic Disease: State of the Art. Curr Atheroscler Rep 2021;23:59. [PMID: 34345933 DOI: 10.1007/s11883-021-00953-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Odi R, Invernizzi RW, Gallily T, Bialer M, Perucca E. Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. Pharmacol Ther 2021;226:107866. [PMID: 33895186 DOI: 10.1016/j.pharmthera.2021.107866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
11 Bays HE, Taub PR, Epstein E, Michos ED, Ferraro RA, Bailey AL, Kelli HM, Ferdinand KC, Echols MR, Weintraub H, Bostrom J, Johnson HM, Hoppe KK, Shapiro MD, German CA, Virani SS, Hussain A, Ballantyne CM, Agha AM, Toth PP. Ten things to know about ten cardiovascular disease risk factors. Am J Prev Cardiol 2021;5:100149. [PMID: 34327491 DOI: 10.1016/j.ajpc.2021.100149] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
12 Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Curr Obes Rep 2021;10:14-30. [PMID: 33410104 DOI: 10.1007/s13679-020-00422-w] [Cited by in Crossref: 52] [Cited by in F6Publishing: 35] [Article Influence: 26.0] [Reference Citation Analysis]
13 Bruno J, Carruthers D, Alemán JO. Prevention and Treatment of Obesity for Cardiovascular Risk Mitigation: Dietary and Pharmacologic Approaches. Contemporary Cardiology 2021. [DOI: 10.1007/978-3-030-78177-4_8] [Reference Citation Analysis]
14 Chintam K, Chang AR. Strategies to Treat Obesity in Patients With CKD.Am J Kidney Dis. 2021;77:427-439. [PMID: 33075388 DOI: 10.1053/j.ajkd.2020.08.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
15 Chao AM, Wadden TA, Berkowitz RI, Quigley K, Silvestry F. The risk of cardiovascular complications with current obesity drugs. Expert Opin Drug Saf 2020;19:1095-104. [PMID: 32750250 DOI: 10.1080/14740338.2020.1806234] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
16 Cataldi M, Cignarelli A, Giallauria F, Muscogiuri G, Barrea L, Savastano S, Colao A; Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group. Cardiovascular effects of antiobesity drugs: are the new medicines all the same? Int J Obes Suppl 2020;10:14-26. [PMID: 32714509 DOI: 10.1038/s41367-020-0015-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 Heffron SP, Parham JS, Pendse J, Alemán JO. Treatment of Obesity in Mitigating Metabolic Risk. Circ Res 2020;126:1646-65. [PMID: 32437303 DOI: 10.1161/CIRCRESAHA.119.315897] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
18 Bays HE. Ten things to know about ten cardiovascular disease risk factors ("ASPC Top Ten - 2020"). Am J Prev Cardiol 2020;1:100003. [PMID: 34327447 DOI: 10.1016/j.ajpc.2020.100003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Purnell JQ. Management of chronic diseases in preventive cardiology: Revisiting “the Problem of Obesity.”. American Journal of Preventive Cardiology 2020;1:100005. [DOI: 10.1016/j.ajpc.2020.100005] [Reference Citation Analysis]
20 Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol 2020;13:53-64. [PMID: 31770497 DOI: 10.1080/17512433.2020.1698291] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 15.0] [Reference Citation Analysis]
21 Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med 2019;7:393. [PMID: 31555707 DOI: 10.21037/atm.2019.07.27] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
22 Oh TJ. The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. J Obes Metab Syndr 2019;28:158-66. [PMID: 31583380 DOI: 10.7570/jomes.2019.28.3.158] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
23 Lee CJ, Kim M, An SJ. Current Treatments on Obesity. Korean J Health Promot 2019;19:171. [DOI: 10.15384/kjhp.2019.19.4.171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]